AMPLY Discovery, a company spun out from Queen’s University Belfast, announced a seed funding round valued at $1.75 million. The company’s latest round, which was led by investor Twin Path Ventures, will help it advance its AI-driven drug discovery platform.
AMPLY works to develop treatments for aggressive cancers, such as triple-negative breast cancer and acute myeloid leukemia. Its goal is to cure diseases caused by patients’ genetic variations. The company’s platform leverages AI, gene sequencing and synthetic biology to identify possible treatments based on biological molecules.
The company is currently developing nebulized treatments for lung infections, leveraging inhalable antimicrobial peptides to deliver drugs straight to a patient’s lungs. Backed by its new capital, AMPLY plans to accelerate the advancement of its drug discovery programs through the preclinical stage.
